For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  CJC-1295 with DAC
Performance & Muscleearly_human

CJC-1295 with DAC

CJC-1295 DAC
Performance & Muscle · CAS 863288-34-0
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Performance & Muscle
Evidence grade
C
PubMed records
32
Female-tagged
2
Sex-analysis
0
CAS
863288-34-0
C
Evidence grade C, Early human data only (Phase 1 / small-n) across 32 indexed studies. How grades work →
Female evidence: None
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH), a 30-amino-acid peptide modified with a Drug Affinity Complex (DAC) built from maleimidopropionic acid. The DAC group binds covalently to circulating serum albumin, which substantially extends the molecule's half-life and makes it a convenient tool for studying sustained receptor engagement in the laboratory.

In preclinical and in-vitro systems, CJC-1295 with DAC has been studied for its activity at the GHRH receptor and its role in the endocrine cascade that regulates growth-hormone release. Because its extended duration keeps receptor exposure relatively constant, researchers examining prolonged GHRH-receptor activation have used it as a research material to characterize signaling dynamics that shorter-acting analogues do not readily model.

What makes this compound a useful entry for an endocrine research catalog is precisely that stability, which lets investigators separate the effects of tonic receptor stimulation from the pulsatile pattern seen with native GHRH. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for in-vitro and laboratory research only.

Summary

CJC-1295 with DAC is a long-acting GHRH analog whose drug-affinity-complex modification extends its half-life by binding serum albumin. Human data are limited to early pharmacokinetic work; it is not an approved therapy and has no female-specific evidence. PubMed counts reflect CJC-1295 broadly, with and without DAC.

Evidence in women

Menstrual cycle
Unstudied
GH secretion is estrogen-sensitive, but CJC-1295 has not been studied across cycle phases.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; GH-axis stimulation in pregnancy has not been evaluated.
Hormonal interactions
Unstudied
No controlled data on interactions with estrogen or contraceptives.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal studies.
Sex differences
Unstudied
The small human literature did not analyze outcomes by sex.

Mechanism

A GHRH analog that binds serum albumin via a drug-affinity complex to prolong stimulation of pituitary growth-hormone release.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)No approved dose; limited human pharmacokinetic data only.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: active malignancy (GH-axis stimulation, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

injection-site reactionsflushing

CJC-1295 with DAC reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for CJC-1295 with DAC

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from CJC-1295 with DAC's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is CJC-1295 with DAC?

CJC-1295 with DAC, also known as CJC-1295 DAC, is a research compound in our performance muscle category. CJC-1295 with DAC is a long-acting GHRH analog whose drug-affinity-complex modification extends its half-life by binding serum albumin.

Is CJC-1295 with DAC studied in women?

CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for CJC-1295 with DAC is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has CJC-1295 with DAC been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; GH-axis stimulation in pregnancy has not been evaluated. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does CJC-1295 with DAC have, and why?

CJC-1295 with DAC carries evidence grade C. Early human data only (Phase 1 / small-n) across 32 indexed studies.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for CJC-1295 with DAC?

No. A female-specific dose for CJC-1295 with DAC is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is CJC-1295 with DAC administered in research?

In the published literature, CJC-1295 with DAC is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for CJC-1295 with DAC?

Effects reported in the research literature include injection-site reactions, flushing. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for CJC-1295 with DAC?

The CAS registry number for CJC-1295 with DAC is 863288-34-0. It is also referred to as CJC-1295 DAC, Modified GRF (1-29) with DAC. Use it to confirm identity against a Certificate of Analysis.

How should CJC-1295 with DAC be stored and handled?

CJC-1295 with DAC sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy CJC-1295 with DAC for research?

For laboratory research use, CJC-1295 with DAC is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy CJC-1295 with DAC at Aurevena Research
Research-use supplier: CJC-1295 with DAC is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

41966639 · 41476424

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
ACE-031C
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 Without DACD
CJC-1295 Without DAC: of 5 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.